Migraine is a chronic neurological disorder that is characterized by an attack of moderate or severe headache and reversible neurological and systemic symptoms. It is estimated that the overall prevalence of migraine in Western countries is 6-8% in men and 15-25% in women. The pathophysiology of migraine is complex and it is still the subject of intensive research. According to the trigeminovascular theory, vasodilation of extracerebral blood vessels and neurogenic inflammation of the dura are the most important pathophysiological features of migraine headaches. Pharmacological therapy of migraine is traditionally divided into acute and preventive. Acute treatment aims to reduce pain and accompanied symptoms, as well as the disability of patients during a migraine attack. Preventive treatment is used to reduce the frequency and severity of expected attacks for people with intense and frequent headaches. Currently, acute migraine attacks are treated with non-opioid analgesics, triptans (5-HT1B/1D receptor agonists), or nasal dihydroergotamine. However, the main disadvantages of this therapy are ineffectiveness in 20-30% of patients and side effects. Preventive therapy is non-specific and involves the empirical administration of drugs from different pharmacotherapeutic groups and does not achieve satisfactory effects in most patients. This diploma thesis gives an overview of new specific migraine drugs that are developed to achieve better efficiency and better, tolerability, and safety compared to previous therapeutic options, with the final goal in increasing the quality of life of patients suffering from migraine. Intensive research on the pathophysiology of migraine has indicated new therapeutic targets and opportunities for the development of new generations of drugs. Based on the understanding of serotonin system pharmacology, 5-HT1F receptor agonists were developed, and the first in class for acute migraine treatment is lasmiditan. Furthermore, clarification of the important role of the CGRP system in migraine pathophysiology has led to the development of CGRP receptor antagonists, the so-called gepants, and monoclonal antibodies targeting the CGRP ligand or CGRP receptor. Ubrogepant and rimegepant were the first two approved receptor antagonists for acute migraine therapy, while monoclonal antibodies are intended for use in the prophylactic therapy of episodic and chronic migraine.